Indegene Helps a Top Biopharma Strengthen Global-to-Local Content Integrity at Scale

Download PDFDownload PDFTalk to UsTalk to Us

The Customer

This global, research-driven biopharmaceutical company is dedicated to improving human and animal health through innovative therapies. Operating across multiple markets, the organization manages a large volume of promotional and medical content that must be localized while remaining aligned with approved global assets. As efforts expanded, the company sought a more structured and scalable content localization strategy to assessing content adoption and consistency across markets.

Team reviewing content metrics together

The Challenge

The organization faced multiple challenges in assessing the consistency and integrity of localized content:

  1. Comparing global and local assets manually was time-consuming and required significant effort across multiple assets and markets.

  2. The organization lacked standardized mechanisms to systematically identify and quantify differences between core and local content, making it difficult to maintain a robust content governance framework.

  3. It was challenging to consistently identify whether localized content represented Reuse, Adapt, or Net-New (RAN) elements.

  4. As the number of assets and markets increased, maintaining consistency in analysis, scoring, and reporting became increasingly difficult.

The Solution

Indegene implemented a content integrity and governance framework that provided a structured approach to systematically compare global assets with their corresponding localized versions, assess content deviations, and measure overall asset integrity. The approach included:

Asset collection and preparation

Gathered and organized global and local assets for analysis.

Asset deconstruction

Deconstructed assets into individual visual and textual elements to enable granular analysis and comparison.

Element mapping

Established element-level correspondence and alignment between core and local assets.

Deviation analysis and RAN classification

Evaluated content variations and inconsistencies across parameters including match text, interpretation, styling, position, and key messaging. Content elements were then classified into reuse, adapt, and net-new categories.

Integrity scoring

Established a structured scoring mechanism to quantify deviations, support pharma content compliance and measure overall asset integrity.

Reporting and insights

Generated standardized reports highlighting reused, adapted, deleted, and net-new elements to provide actionable insights.

Outcomes

The implementation delivered measurable scale and improved visibility into content localization practices across the organization.

5

Brands assessed through a standardized framework

250+

Assets analyzed across multiple content formats

10,000+

Content units assessed for integrity

25+

Markets evaluated for global-to-local consistency

Business Impact

The content integrity framework established a scalable, data-driven approach to assessing how global content was localized across brands and markets. By standardizing assessment rules and scoring criteria, the organization gained a more consistent way to identify and quantify deviations across localized assets.

Element-level analysis provided greater visibility into how content was reused, adapted, created as net-new, or deleted, enabling a more granular understanding of localization practices than asset-level reviews alone. The combination of automated analysis and human validation also supported greater accuracy for complex content and nuanced interpretation.

The framework created a common approach that can be applied across brands, markets, and asset types, providing a stronger foundation for ongoing content integrity assessment and global-to-local content governance.

Looking Ahead

Building on this foundation, the content integrity framework can evolve from retrospective assessment toward more proactive content governance. Future capabilities could include AI-powered deviation detection, integrity checks before and after localization, and intelligent recommendations for content reuse and adaptation. Deeper analytics and integration with existing content workflows could further help identify cross-market trends and reuse opportunities, while enabling the approach to scale across additional brands, markets, and asset types. As these capabilities mature, they can become part of an enterprise AI content platform for pharma, enabling scalable governance, localization oversight, and content integrity management across brands and markets.

Featured Insights